The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Optimising longitudinal plasma-only circulating tumour DNA (ctDNA) for minimal residual disease (MRD) detection with combined genomic/methylation signals to predict recurrence in patients (pts) with resected stage I-III colorectal cancer (CRC) in the UK multicentre prospective study TRACC.
 
Susanna Slater
No Relationships to Disclose
 
Annette Bryant
No Relationships to Disclose
 
Maria Aresu
No Relationships to Disclose
 
Ruwaida Begum
No Relationships to Disclose
 
Hsiang-Chi Chen
No Relationships to Disclose
 
Clare Peckitt
No Relationships to Disclose
 
Retchel Lazaro-Alcausi
No Relationships to Disclose
 
Paul Carter
No Relationships to Disclose
 
Gayathri Anandappa
No Relationships to Disclose
 
Shelize Khakoo
No Relationships to Disclose
 
Graham Branagan
No Relationships to Disclose
 
Nicol George
No Relationships to Disclose
 
Muti Abulafi
No Relationships to Disclose
 
Sarah Duff
No Relationships to Disclose
 
Nicholas West
No Relationships to Disclose
 
Leslie Bucheit
Employment - Guardant Health; Myriad Genetics
Stock and Other Ownership Interests - Guardant Health
 
Thereasa A. Rich
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Ian Chau
Honoraria - Eisai; Lilly; Roche/Genentech; SERVIER
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Roche/Genentech; Seagen; SERVIER; Sotio; Taiho Oncology; Turning Point Therapeutics
Research Funding - Janssen-Cilag (Inst); Lilly (Inst)
 
Naureen Starling
Honoraria - Amgen; GlaxoSmithKline; GlaxoSmithKline; Lilly; Lilly; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Pierre Fabre; Pierre Fabre; Pierre Fabre; Seagen; SERVIER; SERVIER; SERVIER
Consulting or Advisory Role - AstraZeneca; MSD; MSD Oncology; Novartis Pharmaceuticals UK Ltd.; Pfizer
Research Funding - AstraZeneca (Inst); BMS (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - Guardant Health; MSD Oncology
(OPTIONAL) Uncompensated Relationships - Guardant Health
 
David Cunningham
Stock and Other Ownership Interests - OVIBIO
Consulting or Advisory Role - OVIBIO
Research Funding - 4SC (Inst); Bayer (Inst); Celgene (Inst); Clovis Oncology (Inst); Leap Oncology (Inst); Lilly (Inst); MedImmune (Inst); Roche (Inst)